Treatment of Deep Vein Thrombosis (DVT)
Initial Anticoagulation
- The American College of Chest Physicians recommends initiating anticoagulation immediately upon diagnosis of DVT without waiting for confirmatory testing if clinical suspicion is high 1, 2
- Direct oral anticoagulants (DOACs) are the first-line treatment for DVT, preferred over vitamin K antagonists due to superior efficacy, safety, and convenience 1, 2
Choice of Anticoagulant
- DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) are recommended as first-line therapy over warfarin for most patients with DVT 1, 2
- For patients with active cancer, low molecular weight heparin (LMWH) is preferred over DOACs or warfarin 2
Parenteral Anticoagulation
- If using warfarin (vitamin K antagonist), initiate parenteral anticoagulation with LMWH or fondaparinux simultaneously 1
- LMWH or fondaparinux is preferred over unfractionated heparin due to superior efficacy and lower bleeding risk 1, 2
Duration of Anticoagulation
- For provoked DVT (surgery or transient risk factor), treat for exactly 3 months 4, 1, 2
- For unprovoked DVT, minimum 3 months of anticoagulation is required 4, 1, 2
- For unprovoked proximal DVT with low or moderate bleeding risk, extended anticoagulation (no scheduled stop date) is recommended 4, 1, 2
Setting of Care
- Home treatment is recommended over hospitalization for most DVT patients with adequate support systems and access to outpatient care 1
- Early ambulation is preferred over bed rest 5, 1
Interventions Generally NOT Recommended
- Do not use IVC filters in patients who can be anticoagulated 5, 1, 2
- IVC filters are only recommended when anticoagulation is contraindicated (e.g., active bleeding) 5
- Anticoagulation alone is preferred over thrombolysis for most DVT patients 5
Special Considerations and Pitfalls
- Bleeding risk should be assessed before deciding on extended therapy, with high bleeding risk defined as history of major bleeding, thrombocytopenia, severe renal/hepatic impairment, recent surgery, or falls risk 4
- If recurrent VTE occurs on non-LMWH anticoagulant, switch to LMWH 1, 2
- In all patients receiving extended anticoagulation, reassess the risk-benefit ratio at periodic intervals (e.g., annually) 4